Table 2 Proportion of tuberculous (TB) pleuritis and TB lymphadenitis showing a change of > 20% in the levels of biomarkers in response to treatment and the magnitude of fold increase or decrease in the median levels. The biomarkers were detected from the dried blood spots.
Biomarkers | TB lymphadenitis | TB pleuritis | ||||||
|---|---|---|---|---|---|---|---|---|
0–2 months | 0–6 months | 0–2 months | 0–6 months | |||||
n/N (%) | Median folds ↓/↑ | n/N (%) | Median folds ↓/↑ | n/N (%) | Median folds ↓/↑ | n/N (%) | Median folds ↓/↑ | |
MIG | 25/48 (52) | 3↓ | 28/45 (62) | 4↓ | 22/37 (59) | 2↓ | 21/32 (65) | 6↓ |
CCL23 | 42/57 (74) | 3↓ | 36/57 (63) | 3↓ | 18/38 (47) | 3↓ | 23/33 (73) | 3↓ |
IP-10 | 25/45 (56) | 6↓ | 29/43 (67) | 2↓ | 20/38 (53) | 3↓ | 21/33 (64) | 3↓ |
CXCL1 | 17/48 (35) | 3↓ | 27/45 (60) | 3↓ | 9/37 (24) | 2↓ | 22/32 (69) | 3↓ |
CCL20 | 18/29 (62) | 13↓ | 18/35 (51) | 5↓ | 16/28 (57) | 3↓ | 15/23 (62) | 5↓ |
CXCL2 | 33/48 (69) | 5↓ | 27/45 (60) | 2↓ | 27/37 (73) | 2↓ | 22/33 (67) | 2↓ |
MIF | 14/46 (30) | 10↓ | 12/45 (27) | 5↑ | ||||
CXCL11 | 12/48 (25) | 3↓ | 26/45 (58) | 3↓ | 7/38 (18) | 3↓ | 21/33 (64) | 3↓ |
CCL8 | 27/48 (56) | 3↓ | 23/45 (56) | 6↓ | ||||
CCL15 | 25/48 (52) | 2↓ | 22/45 (49) | 2↓ | ||||
CCL2 | 22/37 (59) | 2↑ | 21/32 (66) | 2↑ | ||||
IL-6 | 8/38 (21) | 5↓ | 31/38 (81) | 6↓ | ||||
CCL3 | 12/38 (31) | 2↑ | 16/33 (48) | 2↓ | ||||
CXCL13 | 11/37 (30) | 4↓ | 22/32 (67) | 8↓ | ||||
